Adolor Corp.
700 Pennsylvania Drive
Exton,
PA 19341
United States - Map
Phone: 484-595-1500
Fax: 484-595-1515
Web Site: http://www.adolor.com
| Adolor Corporation engages in the discovery, development, and commercialization of prescription pain management products primarily in the United States. The company’s lead product candidates include Entereg, which is a small molecule, mu-opioid receptor antagonist designed to block the unwanted effects of opioid analgesics on the gastrointestinal tract; and Delta opioid receptor agonists that is in Phase I clinical trail for various pain indications. It also offers a product that combines alvimopan with an opioid analgesic. Adolor Corporation has collaboration agreements with GlaxoSmithKline for the development and commercialization of Entereg in multiple indications; and Pfizer for the development and commercialization of two Delta agonists for pain. In addition, it has various discovery research programs focused on the identification of novel compounds for the treatment of pain. The company was founded in 1993 and is based in Exton, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael R. Dougherty , 50
Chief Exec. Officer, Pres, Director and Member of Secondary Committee on Options |
N/A
| N/A | Dr. David Jackson M.D., 60
Corp. Medical Advisor |
N/A
| N/A | Mr. Stephen Webster ,
Chief Financial Officer and Sr. VP of Fin. |
N/A
| N/A | Dr. Eliseo Oreste Salinas MD, MSc, 52
Chief Medical Officer and Sr. VP of R&D |
N/A
| N/A | Mr. John M. Limongelli Esq.,
Sr. VP, Sec. and Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.83% Nasdaq 0.00%
Profile
